HC Wainwright Cuts Inovio Pharmaceuticals (NASDAQ:INO) Price Target to $5.00

Inovio Pharmaceuticals (NASDAQ:INO) had its price target lowered by HC Wainwright from $12.00 to $5.00 in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q4 2024 earnings at ($1.03) EPS, FY2024 earnings at ($4.39) EPS, Q1 2025 earnings at ($1.08) EPS, Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.68) EPS and FY2025 earnings at ($3.35) EPS.

INO has been the subject of several other reports. Oppenheimer lowered their price objective on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a report on Monday. Royal Bank of Canada reduced their price objective on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Friday, November 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Inovio Pharmaceuticals presently has an average rating of “Hold” and an average price target of $38.00.

Inovio Pharmaceuticals Trading Down 1.5 %

NASDAQ INO opened at $3.97 on Monday. The company’s fifty day moving average price is $5.61 and its two-hundred day moving average price is $8.00. Inovio Pharmaceuticals has a 12 month low of $3.85 and a 12 month high of $14.75.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in INO. BNP Paribas Financial Markets increased its position in Inovio Pharmaceuticals by 177.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 3,630 shares during the period. SG Americas Securities LLC bought a new position in Inovio Pharmaceuticals in the 3rd quarter valued at about $71,000. The Manufacturers Life Insurance Company acquired a new position in Inovio Pharmaceuticals during the 2nd quarter valued at about $82,000. Signature Estate & Investment Advisors LLC bought a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter worth about $88,000. Finally, MetLife Investment Management LLC lifted its stake in shares of Inovio Pharmaceuticals by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 8,546 shares during the period. 26.79% of the stock is currently owned by institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.